Climb Bio Inc (CLYM)

$1.90 +0.03 (1.60%)
Market Cap 127.50M
Revenue (ttm) 0.00
Net Income (ttm) -73.90M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 389,000
Avg Vol 668,166
Day's Range N/A - N/A
Shares Out 68.18M
Stochastic %K 65%
Beta -0.06
Analysts Strong Sell
Price Target $9.20

Company Profile

Climb Bio, Inc., a clinical-stage biotechnology company, focuses on developing therapies for immune-mediated diseases. The company develops budoprutug, an anti-CD19 monoclonal antibody for the treatment of B-cell mediated diseases. It is also developing budoprutug IV for the treatment of primary membranous nephropathy, immune thrombocytopenia, and systemic lupus erythematosus. In addition, the company is developing CLYM116, a preclinical stage anti A Proliferation-inducing Ligand (APRIL) monoclo...

Industry: Biotechnology
Sector: Healthcare
Phone: 866 857 2596
Address:
20 William Street, Suite 145, Wellesley Hills, United States
Jl37
Jl37 Nov. 12 at 1:46 PM
$CLYM what’s with the pre-market big swings?
0 · Reply
Fakhrul123
Fakhrul123 Nov. 11 at 8:03 PM
$CLYM
0 · Reply
Fakhrul123
Fakhrul123 Nov. 11 at 8:02 PM
$CLYM $3 soon
0 · Reply
Jl37
Jl37 Nov. 11 at 5:48 PM
$CLYM
0 · Reply
Jl37
Jl37 Nov. 10 at 3:15 PM
$CLYM
0 · Reply
d_risk
d_risk Nov. 6 at 4:39 PM
$CLYM - Climb Bio, Inc. - 10Q - Updated Risk Factors CLYM’s latest 10-Q risk factors spotlight expanded pipeline and Mabworks deal, mounting net losses, new financial obligations from legacy agreements, greater detail on funding needs, regulatory and litigation uncertainties, supply chain and trade risks, intensified IP and patent challenges, and new disclosures on stock ownership concentration, market volatility, and global economic headwinds. #Biotechnology #IntellectualProperty #RegulatoryUncertainty #FinancialRisk #PharmaceuticalPipeline 🟢 Added 🟠 Removed https://d-risk.ai/CLYM/10-Q/2025-11-06
0 · Reply
LamboSUV
LamboSUV Nov. 5 at 3:31 PM
$CLYM Let's go. I want 30.
0 · Reply
Fakhrul123
Fakhrul123 Nov. 3 at 7:33 AM
$CLYM $2.5 this week!
0 · Reply
__SquuezedChronometer_
__SquuezedChronometer_ Nov. 2 at 12:00 PM
Next major retail squeeze candidate right here $TNMG $CLYM $HUHU $ENGS 2
0 · Reply
Invest2live
Invest2live Oct. 31 at 8:57 PM
$CLYM $IBIO $NGD $IBIO 87% already; keep up the good work. Congrats 🎊 🎉🎈
1 · Reply
Latest News on CLYM
Climb Bio Reports Third Quarter 2025 Financial Results and Provides Business Updates

Nov 6, 2025, 7:01 AM EST - 8 days ago

Climb Bio Reports Third Quarter 2025 Financial Results and Provides Business Updates

Climb Bio to Present at Upcoming Investor Conferences

Nov 3, 2025, 7:00 AM EST - 11 days ago

Climb Bio to Present at Upcoming Investor Conferences

Climb Bio Names Adam Villa as SVP, Technical Operations and Ashley Jones as SVP, People & Workforce Strategy

Oct 21, 2025, 7:00 AM EDT - 24 days ago

Climb Bio Names Adam Villa as SVP, Technical Operations and Ashley Jones as SVP, People & Workforce Strategy

Climb Bio to Present Data at American Society of Nephrology (ASN) Kidney Week 2025

Oct 17, 2025, 7:00 AM EDT - 4 weeks ago

Climb Bio to Present Data at American Society of Nephrology (ASN) Kidney Week 2025

Climb Bio Appoints Susan Altschuller, Ph.D., MBA as Chief Financial Officer

Oct 1, 2025, 7:00 AM EDT - 6 weeks ago

Climb Bio Appoints Susan Altschuller, Ph.D., MBA as Chief Financial Officer

Climb Bio Announces CLYM116 Preclinical Data Highlighting Potential for Best-In-Class Therapeutic for IgAN

Sep 29, 2025, 7:00 AM EDT - 6 weeks ago

Climb Bio Announces CLYM116 Preclinical Data Highlighting Potential for Best-In-Class Therapeutic for IgAN

Climb Bio to Host Webcast Highlighting CLYM116 and the IgA Nephropathy (IgAN) Opportunity on September 29, 2025

Sep 4, 2025, 7:00 AM EDT - 2 months ago

Climb Bio to Host Webcast Highlighting CLYM116 and the IgA Nephropathy (IgAN) Opportunity on September 29, 2025

UPDATE – Climb Bio to Present at Upcoming September 2025 Investor Conferences

Aug 25, 2025, 2:41 PM EDT - 2 months ago

UPDATE – Climb Bio to Present at Upcoming September 2025 Investor Conferences

Climb Bio to Present at Upcoming September 2025 Investor Conferences

Aug 25, 2025, 7:00 AM EDT - 2 months ago

Climb Bio to Present at Upcoming September 2025 Investor Conferences

Climb Bio Reports Second Quarter 2025 Financial Results and Provides Business Updates

Aug 12, 2025, 7:00 AM EDT - 3 months ago

Climb Bio Reports Second Quarter 2025 Financial Results and Provides Business Updates

Climb Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

May 19, 2025, 4:34 PM EDT - 6 months ago

Climb Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Climb Bio Reports First Quarter 2025 Financial Results and Provides Business Updates

May 14, 2025, 7:00 AM EDT - 6 months ago

Climb Bio Reports First Quarter 2025 Financial Results and Provides Business Updates

Climb Bio Appoints Seasoned Biotech Leaders to Board of Directors

Apr 1, 2025, 7:00 AM EDT - 8 months ago

Climb Bio Appoints Seasoned Biotech Leaders to Board of Directors

Climb Bio to Present at the 24th Annual Needham Virtual Healthcare Conference

Mar 27, 2025, 7:00 AM EDT - 8 months ago

Climb Bio to Present at the 24th Annual Needham Virtual Healthcare Conference

Climb Bio Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Business Updates

Mar 25, 2025, 4:05 PM EDT - 8 months ago

Climb Bio Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Business Updates

Climb Bio Appoints Perrin Wilson, Ph.D., as Chief Business Officer

Feb 24, 2025, 7:00 AM EST - 9 months ago

Climb Bio Appoints Perrin Wilson, Ph.D., as Chief Business Officer

Climb Bio to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Feb 4, 2025, 7:00 AM EST - 10 months ago

Climb Bio to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Climb Bio Expands Pipeline Through an Exclusive License to Develop and Commercialize an Antibody Targeting the APRIL Pathway for IgA Nephropathy

Jan 9, 2025, 7:00 AM EST - 11 months ago

Climb Bio Expands Pipeline Through an Exclusive License to Develop and Commercialize an Antibody Targeting the APRIL Pathway for IgA Nephropathy

Climb Bio to be Added to the Nasdaq Biotechnology Index

Dec 19, 2024, 7:00 AM EST - 11 months ago

Climb Bio to be Added to the Nasdaq Biotechnology Index

Climb Bio Reports Third Quarter 2024 Financial Results and Business Highlights

Nov 12, 2024, 4:05 PM EST - 1 year ago

Climb Bio Reports Third Quarter 2024 Financial Results and Business Highlights

Climb Bio Appoints Douglas E. Williams, Ph.D.

Nov 11, 2024, 7:00 AM EST - 1 year ago

Climb Bio Appoints Douglas E. Williams, Ph.D.

Climb Bio to Provide Budoprutug Development Strategy and Corporate Update at Virtual Investor Event

Oct 15, 2024, 7:00 AM EDT - 1 year ago

Climb Bio to Provide Budoprutug Development Strategy and Corporate Update at Virtual Investor Event

Climb Bio Announces Abstract Selected for Presentation at the American Society of Nephrology Kidney Week 2024

Oct 11, 2024, 12:30 PM EDT - 1 year ago

Climb Bio Announces Abstract Selected for Presentation at the American Society of Nephrology Kidney Week 2024

Climb Bio to Present at William Blair's Upcoming Conference Event on Transforming Autoimmune Diseases by Targeting CD19

Oct 4, 2024, 7:00 AM EDT - 1 year ago

Climb Bio to Present at William Blair's Upcoming Conference Event on Transforming Autoimmune Diseases by Targeting CD19

Climb Bio to Host Virtual Investor Event on October 15, 2024

Oct 3, 2024, 10:00 AM EDT - 1 year ago

Climb Bio to Host Virtual Investor Event on October 15, 2024

Eliem Therapeutics Announces Rebranding and Corporate Name Change to Climb Bio, Inc.

Oct 2, 2024, 9:00 AM EDT - 1 year ago

Eliem Therapeutics Announces Rebranding and Corporate Name Change to Climb Bio, Inc.

Eliem Therapeutics to Participate at the Stifel 2024 Virtual Immunology and Inflammation Summit

Sep 11, 2024, 7:00 AM EDT - 1 year ago

Eliem Therapeutics to Participate at the Stifel 2024 Virtual Immunology and Inflammation Summit

Eliem Therapeutics Announces Additions to its Leadership Team

Aug 26, 2024, 7:00 AM EDT - 1 year ago

Eliem Therapeutics Announces Additions to its Leadership Team

Eliem Therapeutics Reports Second Quarter Financial Results

Aug 14, 2024, 6:05 AM EDT - 1 year ago

Eliem Therapeutics Reports Second Quarter Financial Results

Eliem Therapeutics: Year End 2024 MN Data With Further Potential To Unlock Value

Jun 28, 2024, 1:58 PM EDT - 1 year ago

Eliem Therapeutics: Year End 2024 MN Data With Further Potential To Unlock Value

Eliem Therapeutics Announces its Addition to the Russell 2000® and Russell 3000® Indexes

Jun 28, 2024, 7:00 AM EDT - 1 year ago

Eliem Therapeutics Announces its Addition to the Russell 2000® and Russell 3000® Indexes

Eliem Therapeutics Announces the Closing of its Acquisition of Tenet Medicines and Concurrent $120 Million Private Placement

Jun 27, 2024, 4:01 PM EDT - 1 year ago

Eliem Therapeutics Announces the Closing of its Acquisition of Tenet Medicines and Concurrent $120 Million Private Placement

Eliem Therapeutics Announces Agreement to Acquire Tenet Medicines and Concurrent $120 Million Private Placement

Apr 11, 2024, 7:00 AM EDT - 1 year ago

Eliem Therapeutics Announces Agreement to Acquire Tenet Medicines and Concurrent $120 Million Private Placement

Eliem Therapeutics' stock soars 21% premarket after company says it may sell itself

Jul 20, 2023, 6:57 AM EDT - 2 years ago

Eliem Therapeutics' stock soars 21% premarket after company says it may sell itself

Eliem Therapeutics Announces Plans to Explore Strategic Alternatives

Jul 20, 2023, 6:45 AM EDT - 2 years ago

Eliem Therapeutics Announces Plans to Explore Strategic Alternatives

Eliem Therapeutics Reports First Quarter Financial Results and Business Highlights

May 11, 2023, 4:10 PM EDT - 2 years ago

Eliem Therapeutics Reports First Quarter Financial Results and Business Highlights

Eliem Therapeutics Reports Fourth Quarter and Year-End Financial Results and Business Highlights

Mar 6, 2023, 4:10 PM EST - 2 years ago

Eliem Therapeutics Reports Fourth Quarter and Year-End Financial Results and Business Highlights

Eliem Therapeutics Provides Strategic Update and Announces Leadership Transition

Feb 9, 2023, 4:01 PM EST - 3 years ago

Eliem Therapeutics Provides Strategic Update and Announces Leadership Transition

Eliem Therapeutics at the 5th Annual Evercore ISI HealthCONx Virtual Conference

Nov 30, 2022, 7:00 AM EST - 3 years ago

Eliem Therapeutics at the 5th Annual Evercore ISI HealthCONx Virtual Conference

Eliem Therapeutics Reports Third Quarter Financial and Business Highlights

Nov 14, 2022, 6:10 AM EST - 3 years ago

Eliem Therapeutics Reports Third Quarter Financial and Business Highlights

Eliem Therapeutics to Participate at Two Upcoming Investor Conferences

Nov 8, 2022, 7:00 AM EST - 3 years ago

Eliem Therapeutics to Participate at Two Upcoming Investor Conferences

Eliem Therapeutics Provides Update on Pipeline Progress

Oct 5, 2022, 7:00 AM EDT - 3 years ago

Eliem Therapeutics Provides Update on Pipeline Progress

Eliem Therapeutics Reports Second Quarter Financial and Business Highlights

Aug 15, 2022, 6:10 AM EDT - 3 years ago

Eliem Therapeutics Reports Second Quarter Financial and Business Highlights

Eliem's stock slides 20% after saying it will discontinue development of pain treatment

Aug 2, 2022, 9:33 AM EDT - 3 years ago

Eliem's stock slides 20% after saying it will discontinue development of pain treatment

Eliem Therapeutics Provides ETX-810 Program Update

Aug 2, 2022, 7:00 AM EDT - 3 years ago

Eliem Therapeutics Provides ETX-810 Program Update

Eliem Announces Updated Development Plans and the Advancement of ETX-155 for the Treatment of Major Depressive Disorder

Jul 18, 2022, 7:00 AM EDT - 3 years ago

Eliem Announces Updated Development Plans and the Advancement of ETX-155 for the Treatment of Major Depressive Disorder

Eliem Therapeutics to Host Virtual Investor Event on July 21, 2022

Jul 7, 2022, 7:00 AM EDT - 3 years ago

Eliem Therapeutics to Host Virtual Investor Event on July 21, 2022

Jl37
Jl37 Nov. 12 at 1:46 PM
$CLYM what’s with the pre-market big swings?
0 · Reply
Fakhrul123
Fakhrul123 Nov. 11 at 8:03 PM
$CLYM
0 · Reply
Fakhrul123
Fakhrul123 Nov. 11 at 8:02 PM
$CLYM $3 soon
0 · Reply
Jl37
Jl37 Nov. 11 at 5:48 PM
$CLYM
0 · Reply
Jl37
Jl37 Nov. 10 at 3:15 PM
$CLYM
0 · Reply
d_risk
d_risk Nov. 6 at 4:39 PM
$CLYM - Climb Bio, Inc. - 10Q - Updated Risk Factors CLYM’s latest 10-Q risk factors spotlight expanded pipeline and Mabworks deal, mounting net losses, new financial obligations from legacy agreements, greater detail on funding needs, regulatory and litigation uncertainties, supply chain and trade risks, intensified IP and patent challenges, and new disclosures on stock ownership concentration, market volatility, and global economic headwinds. #Biotechnology #IntellectualProperty #RegulatoryUncertainty #FinancialRisk #PharmaceuticalPipeline 🟢 Added 🟠 Removed https://d-risk.ai/CLYM/10-Q/2025-11-06
0 · Reply
LamboSUV
LamboSUV Nov. 5 at 3:31 PM
$CLYM Let's go. I want 30.
0 · Reply
Fakhrul123
Fakhrul123 Nov. 3 at 7:33 AM
$CLYM $2.5 this week!
0 · Reply
__SquuezedChronometer_
__SquuezedChronometer_ Nov. 2 at 12:00 PM
Next major retail squeeze candidate right here $TNMG $CLYM $HUHU $ENGS 2
0 · Reply
Invest2live
Invest2live Oct. 31 at 8:57 PM
$CLYM $IBIO $NGD $IBIO 87% already; keep up the good work. Congrats 🎊 🎉🎈
1 · Reply
Jl37
Jl37 Oct. 30 at 9:19 PM
$CLYM
0 · Reply
Invest2live
Invest2live Oct. 24 at 10:11 PM
$OPEN 190% already; congrats 🎉 🎈🎊 Checkout $CLYM and $RXRX similar potential
0 · Reply
Invest2live
Invest2live Oct. 22 at 8:54 PM
$ASRT $IBIO $REKR $IBIO 80% in a few days; congrats 🎈 🌿🎉 Checkout $RXRX and $CLYM
0 · Reply
Fakhrul123
Fakhrul123 Oct. 22 at 7:11 AM
$CLYM $3 this week!!!
0 · Reply
Invest2live
Invest2live Oct. 21 at 3:05 PM
$NERV 327% in less than 2 months; congrats 🎊 🌿 🎉 Checkout $CLYM with similar potential as well as $LCTX for longs. Do your DD and get in.
1 · Reply
Invest2live
Invest2live Oct. 21 at 1:53 PM
$CLYM $IBIO $NGD $IBIO 50% already; congrats 🎊 🌿🎈 Checkout $CLYM and $CUE and $LCTX
0 · Reply
Invest2live
Invest2live Oct. 21 at 1:39 PM
$NERV 190% already; congrats 🎊 🌿🎈 Checkout $LCTX and $CLYM as well as $I.XBiO
0 · Reply
Fakhrul123
Fakhrul123 Oct. 20 at 10:55 PM
$CLYM $3 in this week
0 · Reply
_www_larval_com_
_www_larval_com_ Oct. 20 at 7:48 PM
$CLYM has jumped 4% higher to 19% (~1Mv) a few minutes ago, follow for more volatility.
0 · Reply
Chumpchange53
Chumpchange53 Oct. 20 at 4:11 PM
$CLYM BOOOOOOOOYAAAAAAAAAAA!!!!!!!
0 · Reply
Quantumup
Quantumup Oct. 17 at 6:22 PM
H.C. Wainwright on 10/13, 🏁 $CLYM at a Buy-$9, and said, A Next-Generation Developer of Therapies for Autoimmune B Cell-Mediated Diseases. We are initiating coverage of Climb Bio with a Buy rating and 12-month price target of $9 per share. H.C. Wainwright additionally said:
0 · Reply
Rick2058
Rick2058 Oct. 17 at 12:27 PM
$CLYM
0 · Reply